As biopharmaceutical companies were forced to shut down or modify their clinical trials early in the pandemic, many clinical trial sponsors turned to virtual or hybrid trials, telemedicine platforms, remote sensors and real-world evidence (RWE).
A recent survey conducted by BioPharma Dive and data-analytics firm SAS found that almost 65% of biopharma executive respondents are considering or already planning modernization of how they manage data for clinical trials. These modernization plans are designed to make the trials more patient-centric, providing convenience and accessibility for participants. And it looks like modernization will continue even after the pandemic fades. In this playbook, we explore:
Thank you for your interest in the playbook! Click below to get your copy.Download Now
Enter the 6 digit code sent to your mobile number
Click on Resend the verification code again